<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Cell</journal-id><journal-id journal-id-type="iso-abbrev">Hum Cell</journal-id><journal-title-group><journal-title>Human Cell</journal-title></journal-title-group><issn pub-type="ppub">0914-7470</issn><issn pub-type="epub">1749-0774</issn><publisher><publisher-name>Springer Japan</publisher-name><publisher-loc>Japan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3676637</article-id><article-id pub-id-type="pmid">23504277</article-id><article-id pub-id-type="publisher-id">53</article-id><article-id pub-id-type="doi">10.1007/s13577-012-0053-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Proteomic analysis of differential protein expression by brain metastases of gynecological malignancies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yoshida</surname><given-names>Ayako</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Okamoto</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tozawa-Ono</surname><given-names>Akiko</given-names></name><address><phone>+81-44-9778111</phone><fax>+81-44-9772944</fax><email>a2ono@marianna-.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Koizumi</surname><given-names>Hirotaka</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kiguchi</surname><given-names>Kazushige</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ishizuka</surname><given-names>Bunpei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kumai</surname><given-names>Toshio</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Nao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511 Japan </aff><aff id="Aff2"><label>2</label>Department of Diagnostic Pathology, St. Marianna University School of Medicine, Kanagawa, 216-8511 Japan </aff><aff id="Aff3"><label>3</label>Graduate School of Pharmacogenomics, St. Marianna University School of Medicine, Kanagawa, 216-8511 Japan </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>3</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>3</month><year>2013</year></pub-date><pub-date pub-type="ppub"><year>2013</year></pub-date><volume>26</volume><issue>2</issue><fpage>56</fpage><lpage>66</lpage><history><date date-type="received"><day>2</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><p>Brain metastases of gynecological malignancies are rare, but the incidence is increasing. Patients with brain metastases have a poor prognosis, therefore early detection and optimal management is necessary. In order to determine a new biomarker, we aimed to identify proteins that associated with brain metastases. We investigated proteins associated with brain metastases of gynecological malignancies in three patients who underwent surgical resection (stage IIb cervical cancer, stage Ib endometrial cancer, and stage IIIb ovarian cancer). Proteomic analysis was performed on formalin-fixed paraffin-embedded (FFPE) samples of the primary tumors and brain metastases, which were analyzed by liquid chromatography with tandem mass spectrometry. Thereafter, candidate proteins were identified by the Scaffold system and Mascot search program, and were analyzed using western blotting and immunohistochemistry. As a result, a total of 129 proteins were identified. In endometrial and ovarian cancers, western blotting revealed that the expression of alpha-enolase (ENO1) and triosephosphate isomerase (TPI-1) was higher and the expression of Transgelin-2 (TAGLN2) was lower in metastatic tumors than in primary tumors. On the other hand, the expression of TPI-1 and TAGLN2 was lower in metastatic tumors than in primary tumors in cervical cancer. Immunohistochemistry confirmed that ENO1 expression was elevated in the metastatic tumors compared with the primary tumors. In conclusion, the present study showed that FFPE tissue-based proteomics analysis can be powerful tool, and these findings suggested that ENO1, TPI-1, and TAGLN2 may have a role in the development and progression of brain metastasis from gynecological malignancies.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Brain metastasis</kwd><kwd>Gynecological malignancies</kwd><kwd>Alpha-enolase</kwd><kwd>Triosephosphate isomerase</kwd><kwd>Transgelin-2</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Japan Human Cell Society and Springer Japan 2013</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>The incidence rate of gynecological malignancies is increasing in Japan, but mortality is stable due to more effective treatment and better diagnostic techniques. However, the treatment of advanced cancer remains problematic [<xref ref-type="bibr" rid="CR1">1</xref>]. Metastasis is a major cause of morbidity and mortality in cancer patients, so investigation of the mechanisms involved is very important. Metastasis of cancer cells is a highly selective and non-random process that comprises a series of linked events. Various molecular and genetic changes define the multistep process of tumor dissemination, which has been described as the &#x0201c;metastatic cascade&#x0201d; [<xref ref-type="bibr" rid="CR2">2</xref>]. Hematogenous metastasis is a complex biological process that includes the steps of intravasation, transport in the blood, extravasation, and growth in a distant organ [<xref ref-type="bibr" rid="CR3">3</xref>]. For hematogenous metastasis to occur, every step of the cascade must be completed [<xref ref-type="bibr" rid="CR4">4</xref>]. According to the &#x0201c;seed and soil&#x0201d; theory of Paget, organ selectivity of metastasis is based on the interaction between tumor cells (the &#x0201c;seed&#x0201d;) and the microenvironment of the target organ (the &#x0201c;soil&#x0201d;), which supports extravasation, survival, and growth of the metastatic tumor [<xref ref-type="bibr" rid="CR5">5</xref>]. Metastasis of gynecological malignancies can occur via the lymphatic, hematogenous, and transcoelomic routes. For cervical cancer, the most frequent sites of metastasis are the lungs, paraaortic lymph nodes, supraclavicular lymph nodes, and abdominal cavity [<xref ref-type="bibr" rid="CR6">6</xref>]. For endometrial cancer, the most frequent sites are the lung and liver, followed by other sites such as the adrenal gland, breast, bone, skin, and brain [<xref ref-type="bibr" rid="CR7">7</xref>]. In the case of ovarian cancer, transcoelomic metastasis is the most common, followed by pelvic lymph node, peritoneal, lymphatic, and, rarely, by hematogenous spread [<xref ref-type="bibr" rid="CR8">8</xref>]. Metastasis to the brain is one of the most feared complications of cancer, since patients with brain metastasis usually have a poor prognosis and rapidly progressive neurologic symptoms. Consequently, treatment of brain metastases is becoming an increasingly important determinant of the survival time and quality of life for cancer patients, meaning that early detection and optimal management of brain metastases are essential. According to the brain tumor registry of Japan (1984&#x02013;1996), tumors of the lung (52.3&#x000a0;%), breast (8.9&#x000a0;%), and rectum (5.2&#x000a0;%) are most likely to metastasize to the brain, while brain metastasis from gynecological malignancies is rare (1.7&#x000a0;% for uterine cancer and 0.8&#x000a0;% for ovarian cancer) [<xref ref-type="bibr" rid="CR9">9</xref>]. However, a recent study suggested that the incidence of brain metastasis from gynecological malignancies is rising along with the longer survival of patients with these tumors due to effective treatment and the availability of better imaging techniques [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>DNA microarray analysis has now become a standard tool for molecular studies of cancer [<xref ref-type="bibr" rid="CR11">11</xref>]. The ability to complement this approach with methods of proteomic analysis [<xref ref-type="bibr" rid="CR12">12</xref>] is crucial for identification of proteins that may serve as targets for new antibody-based therapeutic strategies [<xref ref-type="bibr" rid="CR13">13</xref>]. Such proteomic research is particularly important for the characterization of gene products contributing to the metastatic potential of cancer [<xref ref-type="bibr" rid="CR14">14</xref>]. Molecular screening of metastases by proteomic analysis has been done in several previous studies, including investigations of breast cancer, hepatocellular carcinoma, and squamous cell carcinoma of the lung [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. However, there has been little proteomic analysis of clinical samples of gynecological malignancies, including brain metastases.</p><p>Therefore, the present study was performed to investigate differential protein expression in patients with brain metastases of gynecological malignancies using proteomic analysis with the hope of identifying potential new tumor markers. To do this, we performed a comparative proteomic analysis of primary and metastatic tumor tissue sample from patients with gynecological cancer by liquid chromatography with tandem mass spectrometry (LC&#x02013;MS/MS).</p></sec><sec id="Sec2"><title>Materials and methods</title><p>Proteomic analysis was performed on formalin-fixed paraffin-embedded samples of primary tumors and brain metastases, which were analyzed by LC&#x02013;MS/MS. Candidate proteins were detected using the Scaffold system and Mascot search program. The expression of some proteins was also assessed by western blotting and immunohistochemistry.</p><sec id="Sec3"><title>Patients</title><p>We reviewed 15 patients with brain metastases of gynecological malignancies. Between 2005 and 2009, 3 of them underwent surgical resection, including 1 patient each with uterine cervical cancer (FIGO stage IIb), endometrial cancer (FIGO stage Ib), and ovarian cancer (FIGO stage IIIb) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Tumor tissue samples were fixed in 10&#x000a0;% buffered formalin for 24&#x02013;48&#x000a0;h and then were embedded in paraffin, after which blocks of these specimens were stored from 2005 to 2009. The study protocol was approved by the Human Ethics Review Committee of St. Marianna University School of Medicine.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Clinical characteristics of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">Patients</th></tr><tr><th align="left">1</th><th align="left">2</th><th align="left">3</th></tr></thead><tbody><tr><td align="left">Diagnosis</td><td align="left">EC</td><td align="left">CeC</td><td align="left">OC</td></tr><tr><td align="left">FIGO stage</td><td align="left">Ib</td><td align="left">IIb</td><td align="left">IIIb</td></tr><tr><td align="left">Histology</td><td align="left">Endometrioid adenocarcinoma, G1</td><td align="left">Squamous cell carcinoma</td><td align="left">Serous adenocarcinoma</td></tr><tr><td align="left">Primary treatment</td><td align="left">Modified radical hysterectomy&#x000a0;+&#x000a0;BSO&#x000a0;+&#x000a0;PLN&#x000a0;+&#x000a0;chemotherapy</td><td align="left">Radical hysterectomy&#x000a0;+&#x000a0;CCRT</td><td align="left">Total hysterectomy&#x000a0;+&#x000a0;BSO&#x000a0;+&#x000a0;omentectomy&#x000a0;+&#x000a0;chemotherapy</td></tr><tr><td align="left">Number of brain metastases</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1</td></tr><tr><td align="left">Treatment of brain metastasis</td><td align="left">Surgery&#x000a0;+&#x000a0;WBRT</td><td align="left">Surgery&#x000a0;+&#x000a0;WBRT</td><td align="left">Surgery&#x000a0;+&#x000a0;WBRT</td></tr><tr><td align="left">Other sites of disease</td><td align="left">None</td><td align="left">LN (paraaortic, Virchow&#x02019;s) pulmonary</td><td align="left">Abdominal</td></tr><tr><td align="left">Survival<sup>a</sup> (months)</td><td align="left">AWD (48)</td><td align="left">DOD (22)</td><td align="left">DOD (4)</td></tr></tbody></table><table-wrap-foot><p>
<italic>EC</italic> endometrial cancer, <italic>CeC</italic> uterine cervical cancer, <italic>OC</italic> ovarian cancer, <italic>CCRT</italic> concurrent chemoradiotherapy, <italic>BSO</italic> bilatelal salpingo-oophorectomy, <italic>PLN</italic> pelvic lymph node dissection, <italic>LN</italic> lymph node, <italic>WBRT</italic> whole brain radiotherapy, <italic>AWD</italic> alive with disease, <italic>DOD</italic> dead of disease</p><p>
<sup>a</sup>Survival from diagnosis of brain metastasis</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec4"><title>Extraction of proteins from tumor tissues</title><p>To minimize contamination of samples by stromal cells, we selected the block that contained the largest amount of tumor tissue from each patient. Extraction of crude proteins from these tissue blocks was carried out as described elsewhere [<xref ref-type="bibr" rid="CR18">18</xref>], with minor modifications. Briefly, 10 tissue sections (each 10&#x000a0;&#x003bc;m thick) were deparaffinized in 1&#x000a0;mL of xylene with gentle agitation for 5&#x000a0;min. After removing the xylene, 1&#x000a0;mL of 100&#x000a0;% ethanol was added and the sections were agitated for 5&#x000a0;min. After centrifugation at 15,000<italic>g</italic> for 10&#x000a0;min, the supernatant was removed and the pellet was thoroughly dried under a vacuum for 10&#x000a0;min. Then, 100&#x000a0;&#x003bc;l of extraction buffer from the Qproteome FFPE Tissue Kit (Qiagen, Valencia, CA, USA) was added to the dewaxed tissue pellet, followed by incubation on ice for 5&#x000a0;min, vortex mixing, and heating at 100&#x000a0;&#x000b0;C for 20&#x000a0;min and 80&#x000a0;&#x000b0;C for 2&#x000a0;h in a Thermomixer at 750&#x000a0;rpm. After centrifugation at 14,000<italic>g</italic> and 4&#x000a0;&#x000b0;C for 15&#x000a0;min, 10&#x000a0;&#x003bc;L of the supernatant was used to measure the protein content by the Lowry method [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec5"><title>Sample preparation and LC&#x02013;MS/MS</title><p>For isolation of tissues and preparation of proteins, the Qproteome FFPE Tissue Kit (Qiagen) was employed according to the manufacturer&#x02019;s recommendations. After the total protein content was measured by the Lowry method, protein samples (50&#x000a0;&#x003bc;g) were divided up for LC&#x02013;MS/MS analysis. These protein samples were digested with trypsin (Protease MAX Surfactant; Promega, Madison, WI, USA) and then extracted with a Zip tip C<sub>18</sub> pipette tip (Promega).</p><p>The resulting peptides were subjected to LC&#x02013;MS/MS analysis using a capillary LC system (Magic2002; Michrom BioResources, Auburn, CA, USA) coupled to an inline nanoelectrospraymass spectrometer (LCQAdvantage; Thermo Finnegan, Waltham, MA, USA) with a silica-coated glass capillary tube (PiclTip; New Objective, Woburn, MA, USA) to obtain a peptide mass fingerprint. Raw LC&#x02013;MS/MS data files were searched by both Mascot and X!Tandem for identification. To generate a statistically valid list of proteins, Scaffold was used to accommodate differences of algorithm and score calculation by the two search engines [<xref ref-type="bibr" rid="CR20">20</xref>]. Each protein identified was assigned a biological process based on information from the international protein index (IPI) human database (European Bioinformatics Institute, 2011) and the Gene Ontology (GO) database (National Center for Biotechnology Information, 2011).</p></sec><sec id="Sec6"><title>Western blotting</title><p>Protein samples (10 &#x003bc;g each) were mixed in sample buffer at 100&#x000a0;&#x000b0;C for 5&#x000a0;min and subjected to SDS-polyacrylamide gel electrophoresis on 10&#x000a0;% polyacrylamide gels. Then, the samples were transferred to enhanced chemiluminescence membranes (ECL; Amersham-Pharmacia Biotech, Buckinghamshire, UK) that had been blocked for 1&#x000a0;h in ECL Advance Blocking Agent. These membranes were incubated with rabbit anti&#x02013;transgelin-2 (TAGLN2) polyclonal antibody (1:200; Sigma, Saint Louis, MO, USA), rabbit anti&#x02013;triosephosphate isomerase 1 (TPI-1) polyclonal antibody (1:200; GeneTex, Irvine, CA, USA), or rabbit anti&#x02013;enolase 1 (ENO1) polyclonal antibody (1:250; Abcam, Cambridge, UK) for 1&#x000a0;h at room temperature. After washing for a total of 30&#x000a0;min with 5 exchanges of Tris buffered saline with Tween 20 (TBS-T), the membranes were incubated with peroxidase-labeled immunoglobulin G of the appropriate species for 1&#x000a0;h at room temperature. After washing a further 5 times with TBS-T, immunoreactive proteins were detected with an ECL Advance Western Blotting Detection System kit (Amersham-Pharmacia Biotech, Piscataway, NJ, USA) and an LAS-3000(Fujifilm, Tokyo, Japan). After stripping, the membranes were reprobed with mouse anti-actin monoclonal antibody (1:2,000; Sigma) as a loading control.</p></sec><sec id="Sec7"><title>Immunohistochemistry</title><p>Tissue blocks of the primary tumors and brain metastases were cut into 3-&#x003bc;m sections, which were dewaxed, rehydrated, and incubated with 3&#x000a0;% hydrogen peroxide for 5&#x000a0;min to block endogenous peroxidases. Then, the sections were incubated with anti-ENO1 monoclonal antibody (1:100; Abcam) at room temperature for 1&#x000a0;h. After washing 3 times with phosphate-buffered saline, the sections were incubated with a horseradish peroxidase-labeled polymer-conjugated anti-mouse secondary antibody (ENVISION&#x000a0;+&#x000a0;; Dako, Copenhagen, Denmark) for 30&#x000a0;min at room temperature. Finally, color was developed with 3,3&#x02032;-diaminobenzidine tetrahydrochloride.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Proteins identified in the primary and metastatic tumors</title><p>Raw files of LC&#x02013;MS/MS data were searched by both Mascot and X!Tandem for identification of proteins. To generate a statistically valid protein list, Scaffold was used to accommodate differences of algorithm and score calculation between the two search engines [<xref ref-type="bibr" rid="CR20">20</xref>]. A total of 129 proteins were identified (76 in the primary tumors and 101 in the metastatic tumors) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Comparison of the primary and metastatic tumors revealed the differential expression of 81 proteins (28 in the solely primary tumors and 53 in the solely metastatic tumors) and the shared expression of 48 other proteins (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>List of total expressed protein (protein identification probability)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">No.</th><th align="left" rowspan="3">Protein name</th><th align="left" colspan="6">Observed sample (probability %)</th></tr><tr><th align="left" colspan="3">Primary tumor</th><th align="left" colspan="3">Metastatic tumor</th></tr><tr><th align="left">EC</th><th align="left">CeC</th><th align="left">OC</th><th align="left">EC</th><th align="left">CeC</th><th align="left">OC</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Actin, cytoplasmic 1</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td></tr><tr><td char="." align="left">2</td><td align="left">Histone H4</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td></tr><tr><td char="." align="left">3</td><td align="left">Keratin, type II cytoskeletal 1</td><td char="." align="char">100</td><td char="." align="char">90</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td></tr><tr><td char="." align="left">4</td><td align="left">Hemoglobin subunit beta</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">89</td><td char="." align="char">100</td><td char="." align="char">100</td></tr><tr><td char="." align="left">5</td><td align="left">Histone H1.2</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">89</td><td char="." align="char">100</td><td char="." align="char">100</td><td align="left"/></tr><tr><td char="." align="left">6</td><td align="left">Uncharacterized protein</td><td char="." align="char">93</td><td char="." align="char">100</td><td char="." align="char">98</td><td char="." align="char">100</td><td align="left"/><td char="." align="char">100</td></tr><tr><td align="left">7</td><td align="left">Hemoglobin subunit alpha</td><td char="." align="char">93</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">89</td><td char="." align="char">100</td><td char="." align="char">89</td></tr><tr><td align="left">8</td><td align="left">Histone H2A type 1-B/E</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">89</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">89</td></tr><tr><td align="left">9</td><td align="left">Tubulin, beta</td><td align="left"/><td align="left"/><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td></tr><tr><td align="left">10</td><td align="left">Keratin, type I cytoskeletal 10</td><td char="." align="char">93</td><td char="." align="char">100</td><td align="left"/><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">89</td></tr><tr><td align="left">11</td><td align="left">Glyceraldehyde-3-phosphate dehydrogenase</td><td char="." align="char">100</td><td char="." align="char">90</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td></tr><tr><td align="left">12</td><td align="left">Histone H3.2</td><td char="." align="char">100</td><td char="." align="char">90</td><td char="." align="char">89</td><td char="." align="char">94</td><td char="." align="char">100</td><td char="." align="char">89</td></tr><tr><td align="left">13</td><td align="left">Histone H2B type 1-L</td><td char="." align="char">98</td><td char="." align="char">99</td><td char="." align="char">89</td><td char="." align="char">89</td><td char="." align="char">99</td><td align="left"/></tr><tr><td align="left">14</td><td align="left">Isoform alpha-enolase of Alpha-enolase</td><td align="left"/><td align="left"/><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">100</td></tr><tr><td align="left">15</td><td align="left">Triosephosphate isomerase isoform 2</td><td char="." align="char">99</td><td align="left"/><td align="left"/><td char="." align="char">100</td><td char="." align="char">100</td><td char="." align="char">98</td></tr><tr><td align="left">16</td><td align="left">Vimentin</td><td align="left"/><td align="left"/><td char="." align="char">100</td><td align="left"/><td char="." align="char">90</td><td char="." align="char">100</td></tr><tr><td align="left">17</td><td align="left">IGL@ protein</td><td align="left"/><td char="." align="char">100</td><td align="left"/><td char="." align="char">89</td><td char="." align="char">90</td><td char="." align="char">89</td></tr><tr><td align="left">18</td><td align="left">TUBA1C protein</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td char="." align="char">100</td><td char="." align="char">98</td></tr><tr><td align="left">19</td><td align="left">Keratin, type I cytoskeletal 9</td><td char="." align="char">100</td><td align="left"/><td align="left"/><td char="." align="char">99</td><td align="left"/><td align="left"/></tr><tr><td align="left">20</td><td align="left">Beta-actin-like protein 2</td><td align="left"/><td char="." align="char">90</td><td char="." align="char">89</td><td align="left"/><td char="." align="char">90</td><td char="." align="char">89</td></tr><tr><td align="left">21</td><td align="left">Neutrophil defensin 1</td><td char="." align="char">93</td><td char="." align="char">90</td><td align="left"/><td char="." align="char">100</td><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">22</td><td align="left">Isoform M1 of Pyruvate kinase isozymes M1/M2</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td char="." align="char">100</td><td char="." align="char">98</td></tr><tr><td align="left">23</td><td align="left">Heat shock protein beta-1</td><td align="left"/><td char="." align="char">100</td><td char="." align="char">89</td><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">24</td><td align="left">Ubiquitin-40S ribosomal protein S27a</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td char="." align="char">99</td><td align="left"/><td align="left"/></tr><tr><td align="left">25</td><td align="left">Nuclease-sensitive element-binding protein 1</td><td char="." align="char">93</td><td char="." align="char">90</td><td align="left"/><td char="." align="char">89</td><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">26</td><td align="left">23&#x000a0;kDa protein</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td char="." align="char">90</td><td char="." align="char">89</td></tr><tr><td align="left">27</td><td align="left">Keratin, type I cytoskeletal 19</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td char="." align="char">90</td><td char="." align="char">89</td></tr><tr><td align="left">28</td><td align="left">Collagen alpha-2(I) chain</td><td char="." align="char">93</td><td char="." align="char">90</td><td char="." align="char">89</td><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">29</td><td align="left">Protein S100-A8</td><td char="." align="char">100</td><td char="." align="char">90</td><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">30</td><td align="left">Heat shock 70&#x000a0;kDa protein 1A/1B</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td char="." align="char">89</td><td char="." align="char">100</td><td align="left"/></tr><tr><td align="left">31</td><td align="left">Protein S100-A9</td><td align="left"/><td char="." align="char">100</td><td align="left"/><td char="." align="char">100</td><td align="left"/><td align="left"/></tr><tr><td align="left">32</td><td align="left">Isoform 1 of Fibronectin</td><td char="." align="char">93</td><td char="." align="char">90</td><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">33</td><td align="left">Galectin-1</td><td char="." align="char">93</td><td char="." align="char">90</td><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">34</td><td align="left">Isoform 1 of L-lactate dehydrogenase A chain</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">35</td><td align="left">PRO2275</td><td align="left"/><td char="." align="char">90</td><td char="." align="char">89</td><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">36</td><td align="left">60S ribosomal protein L8</td><td char="." align="char">43</td><td char="." align="char">90</td><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">37</td><td align="left">N-acetyltransferase ESCO2</td><td char="." align="char">89</td><td align="left"/><td align="left"/><td char="." align="char">35</td><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">38</td><td align="left">cDNA FLJ45139 fis, clone BRAWH3039623</td><td align="left"/><td char="." align="char">88</td><td align="left"/><td char="." align="char">30</td><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">39</td><td align="left">40S ribosomal protein S25</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">40</td><td align="left">Isoform 1 of Heterogeneous nuclear ribonucleoprotein K</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">41</td><td align="left">Uncharacterized protein</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">42</td><td align="left">14-3-3 protein theta</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">43</td><td align="left">Putative annexin A2-like protein</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">44</td><td align="left">Peptidyl-prolyl cis&#x02013;trans isomerase A</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">45</td><td align="left">Fructose-bisphosphate aldolase A</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">46</td><td align="left">Glutathione S-transferase P</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">47</td><td align="left">Profilin-1</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">48</td><td align="left">Histone H2A type 2-B</td><td align="left"/><td char="." align="char">86</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">49</td><td align="left">Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td><td char="." align="char">90</td><td char="." align="char">73</td></tr><tr><td align="left">50</td><td align="left">Isoform 1 of Glial fibrillary acidic protein</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td char="." align="char">100</td></tr><tr><td align="left">51</td><td align="left">Ubiquitin-like modifier-activating enzyme 1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td></tr><tr><td align="left">52</td><td align="left">Elongation factor 1-alpha 1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td><td align="left"/></tr><tr><td align="left">53</td><td align="left">Beta-2-microglobulin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td char="." align="char">89</td></tr><tr><td align="left">54</td><td align="left">14-3-3 protein zeta/delta</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td char="." align="char">89</td></tr><tr><td align="left">55</td><td align="left">Isoform Long of 14-3-3 protein beta/alpha</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">56</td><td align="left">ATP synthase subunit alpha, mitochondrial</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">57</td><td align="left">Putative uncharacterized protein</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">58</td><td align="left">Fibrinogen beta chain</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td><td align="left"/><td align="left"/></tr><tr><td align="left">59</td><td align="left">Heat shock protein HSP 90-beta</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td></tr><tr><td align="left">60</td><td align="left">Keratin, type I cytoskeletal 18</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td></tr><tr><td align="left">61</td><td align="left">Isoform 1 of heterogeneous nuclear ribonucleoprotein A3</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td><td align="left"/></tr><tr><td align="left">62</td><td align="left">Stress-70 protein, mitochondrial</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td></tr><tr><td align="left">63</td><td align="left">Keratin, type II cytoskeletal 8</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td></tr><tr><td align="left">64</td><td align="left">ATP synthase subunit beta, mitochondrial</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">100</td></tr><tr><td align="left">65</td><td align="left">Peroxiredoxin-1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">66</td><td align="left">Histone H1x</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">67</td><td align="left">60S ribosomal protein L7a</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">68</td><td align="left">Isoform short of heterogeneous nuclear ribonucleoprotein U</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">69</td><td align="left">Isoform 3 of probable ATP-dependent RNA helicase DDX17</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">70</td><td align="left">Homeobox protein HMX3</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">90</td><td align="left"/></tr><tr><td align="left">71</td><td align="left">Isoform 1 of tropomyosin alpha-4 chain</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">72</td><td align="left">Isocitrate dehydrogenase [NADP], mitochondrial</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">73</td><td align="left">Poly(rC)-binding protein 1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">74</td><td align="left">Thioredoxin-dependent peroxide reductase, mitochondrial</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">75</td><td align="left">NHP2-like protein 1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">76</td><td align="left">Phosphoglycerate kinase 1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">77</td><td align="left">Elongation factor 2</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">78</td><td align="left">Thioredoxin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">79</td><td align="left">Phosphoglycerate mutase 2</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">80</td><td align="left">Isoform 1 of clusterin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">81</td><td align="left">Isoform mitochondrial of fumarate hydratase, mitochondrial</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">82</td><td align="left">Isoform 2 of protein disulfide-isomerase A6</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">83</td><td align="left">Isoform 1 of 3,2-trans-enoyl-CoA isomerase, mitochondrial</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">84</td><td align="left">Isoform 2 of heterogeneous nuclear ribonucleoprotein A/B</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">85</td><td align="left">Keratin, type II cytoskeletal 1b</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">86</td><td align="left">32&#x000a0;kDa protein</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">87</td><td align="left">Hemoglobin subunit delta</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">88</td><td align="left">14&#x000a0;kDa protein</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td></tr><tr><td align="left">89</td><td align="left">Isoform 1 of heat shock cognate 71&#x000a0;kDa protein</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">90</td><td align="left">Histone H2B type 2-E</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">91</td><td align="left">Plasminogen</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">92</td><td align="left">Keratin, type II cytoskeletal 2 epidermal</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">93</td><td align="left">Isoform 1 of heterogeneous nuclear ribonucleoprotein D0</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">94</td><td align="left">ADP-ribosylation factor 1</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">95</td><td align="left">Isoform A1-B of heterogeneous nuclear ribonucleoprotein A1</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">96</td><td align="left">Isoform C1 of heterogeneous nuclear ribonucleoproteins C1/C2</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">97</td><td align="left">Isoform 1 of myelin proteolipid protein</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">98</td><td align="left">14-3-3 protein gamma</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">99</td><td align="left">Isoform 1 of brain acid soluble protein 1</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">100</td><td align="left">cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">101</td><td align="left">Isoform 2 of Nucleophosminisoform 2 of nucleophosmin</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/></tr><tr><td align="left">102</td><td align="left">Myosin light chain 6B</td><td char="." align="char">93</td><td char="." align="char">90</td><td char="." align="char">89</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">103</td><td align="left">60S ribosomal protein L7</td><td char="." align="char">93</td><td char="." align="char">99</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">104</td><td align="left">Histone H1.5</td><td char="." align="char">93</td><td char="." align="char">98</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">105</td><td align="left">Transgelin</td><td align="left"/><td char="." align="char">100</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">106</td><td align="left">Phosphatidylethanolamine-binding protein 1</td><td char="." align="char">93</td><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">107</td><td align="left">Transgelin-2</td><td align="left"/><td char="." align="char">90</td><td char="." align="char">89</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">108</td><td align="left">Isoform long of splicing factor, proline- and glutamine-rich</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">109</td><td align="left">40S ribosomal protein S14</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">110</td><td align="left">Myosin regulatory light chain 12B</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">111</td><td align="left">40S ribosomal protein S13</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">112</td><td align="left">Isoform 1 of Protein shisa-6 homolog</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">113</td><td align="left">Histone H2A.V</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">114</td><td align="left">Lumican</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">115</td><td align="left">Prolargin</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">116</td><td align="left">HLA class I histocompatibility antigen, Cw-1 alpha chain</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">117</td><td align="left">Isoform 2 of microtubule-actin cross-linking factor 1, isoforms 1/2/3/5</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">118</td><td align="left">Macrophage migration inhibitory factor</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">119</td><td align="left">Isoform 1 of FYVE, RhoGEF and PH domain-containing protein 5</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">120</td><td align="left">31&#x000a0;kDa protein</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">121</td><td align="left">Centrosomal protein 170&#x000a0;kDa</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">122</td><td align="left">Isoform 1 of DNA polymerase theta</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">123</td><td align="left">Isoform 1 of serine/arginine-rich splicing factor 7</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">124</td><td align="left">Heterogeneous nuclear ribonucleoprotein H</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">125</td><td align="left">Hypothetical protein LOC80164</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">126</td><td align="left">Acyl-CoA-binding domain-containing protein 7-like</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">127</td><td align="left">NOL1/NOP2/Sun domain family member 4</td><td align="left"/><td align="left"/><td char="." align="char">89</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">128</td><td align="left">Actin, alpha skeletal muscle</td><td align="left"/><td char="." align="char">90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td char="." align="left">129</td><td align="left">60S ribosomal protein L31</td><td char="." align="char">93</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>Protein expression profiles of metastatic and primary tumor determined by LS/MS/MS. List of proteins found differentially expression between brain metastatic tumor and primary tumor. Protein identification probability is shown by the percentage of total spectra</p><p>
<italic>EC</italic> Endometrial cancer,<italic> CeC</italic> uterine cervical cancer, <italic>OC</italic> ovarian cancer</p></table-wrap-foot></table-wrap>
<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Protein expression in primary and metastatic tumors. <bold>a</bold> Venn diagram showing the differential expression of 129 proteins by primary and metastatic tumors (76 in primary tumors and 101 in metastatic tumors). <bold>b</bold> Distribution of proteins related to different biological processes. <bold>c</bold> Comparison of proteins expressed by primary and metastatic tumors. The expression of proteins related to developmental and multicellular organismal process was lower in metastatic tumors than in primary tumors, whereas the expression of proteins related to metabolic processes was higher in metastatic tumors than in primary tumors</p></caption><graphic xlink:href="13577_2012_53_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec10"><title>Proteomes of the primary and metastatic tumors</title><p>Each protein that we identified was assigned a biological process based on information from the IPI and GO databases to understand their role. If a protein was known to participate in more than one biological process, it was included in multiple categories. Classification according to biological processes showed that the majority of the proteins were involved in metabolic processes, developmental processes, or multicellular organismal process (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b), with some interesting proteins that have been implicated in tumorigenesis. In metastatic tumors, proteins related to developmental and multicellular organismal process were decreased compared with primary tumors (4.7 and 3.2&#x000a0;%, respectively), while proteins related to metabolic processes were increased compared with primary tumors (5.3&#x000a0;%) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c).</p></sec><sec id="Sec11"><title>Differential protein expression by primary and metastatic tumors</title><p>Comparison of the distribution of proteins between primary and metastatic tumors revealed differences of proteins involved in metabolic, developmental, and multicellular organismal processes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Based on the results of searches carried out in the primary and metastatic tumors, eight candidate proteins were selected (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Among these proteins, TAGLN2, TPI-1, and ENO1 were subjected to further investigation.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Protein expression profile of the primary and metastatic tumors</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Protein category</th><th align="left" rowspan="3">Gene</th><th align="left" rowspan="3">p<italic>I</italic>
</th><th align="left" rowspan="3">MW</th><th align="left" colspan="6">Observed sample (Mascot score)</th></tr><tr><th align="left" colspan="3">Primary tumors</th><th align="left" colspan="3">Metastatic tumors</th></tr><tr><th align="left">EC</th><th align="left">CeC</th><th align="left">OC</th><th align="left">EC</th><th align="left">CeC</th><th align="left">OC</th></tr></thead><tbody><tr><td align="left" colspan="10">Metabolic process</td></tr><tr><td align="left">&#x000a0;Triosephosphate isomerase 1</td><td align="left">TPI1</td><td char="." align="char">5.7</td><td char="." align="char">30.8</td><td char="." align="left">+(111)</td><td align="left"/><td align="left">&#x02013;</td><td char="." align="left">+(200)</td><td char="." align="left">+(96)</td><td char="." align="left">+(60)</td></tr><tr><td align="left">&#x000a0;Alpha-enolase</td><td align="left">ENO1</td><td char="." align="char">7.0</td><td char="." align="char">47.1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="left">+(112)</td><td char="." align="left">+(206)</td><td char="." align="left">+(94)</td><td char="." align="left">+(28)</td></tr><tr><td align="left">&#x000a0;ATP synthase subunit alpha, mitochondrial</td><td align="left">ATP5A</td><td char="." align="char">9.2</td><td char="." align="char">59.7</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="left">+(62)</td><td char="." align="left">+(72)</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;Tubulin beta</td><td align="left">TUBB</td><td char="." align="char">7.8</td><td char="." align="char">47.0</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="left">+(58)</td><td char="." align="left">+(96)</td><td char="." align="left">+(124)</td><td char="." align="left">+(97)</td></tr><tr><td align="left">&#x000a0;60S ribosomal protein L7</td><td align="left">RPL7</td><td char="." align="char">10.7</td><td char="." align="char">29.2</td><td char="." align="left">+(63)</td><td char="." align="left">+(59)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="10">Developmental precess</td></tr><tr><td align="left">&#x000a0;Myosin light chain 6B</td><td align="left">MYL6</td><td char="." align="char">5.6</td><td char="." align="char">22.8</td><td char="." align="left">+(52)</td><td align="left">&#x02013;</td><td char="." align="left">+(75)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;Transgelin-2</td><td align="left">TAGLN2</td><td char="." align="char">8.4</td><td char="." align="char">22.4</td><td align="left">&#x02013;</td><td char="." align="left">+(66)</td><td char="." align="left">+(86)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="10">Multicellular organismal process</td></tr><tr><td align="left">&#x000a0;Phosphatidylethanolamine-binding protein 1</td><td align="left">PEBP1</td><td char="." align="char">8.6</td><td char="." align="char">26.4</td><td char="." align="left">+(40)</td><td char="." align="left">+(35)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><p> Probabilities of 95 and 80&#x000a0;% were used as the cutoff values for identification of peptides and proteins, respectively, excluding proteins identified with a lesser probability</p><p>
<italic>EC</italic> Endometrial cancer,<italic> CeC</italic> uterine cervical cancer, <italic>OC</italic> ovarian cancer</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Confirmation of differential protein expression</title><p>To more precisely evaluate TAGLN2, TPI-1, and ENO1 expression by gynecological cancers, western blotting was carried out using proteins extracted from the 3 primary and 3 metastatic tumors. In endometrial and ovarian cancers, the expression of TPI-1 and ENO1 was higher in metastatic tumors than in primary tumors; this finding was consistent with the reported role of these proteins in promoting tumor cell survival and proliferation [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. However, the expression of TAGLN2 was lower in metastatic tumors than in primary tumors; this finding was consistent with the reported role of TAGLN2 as a tumor suppressor [<xref ref-type="bibr" rid="CR23">23</xref>]. Further, in cervical cancer, the expression of TAGLN2 and TPI-1 was lower in metastatic tumors than in primary tumors (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Western blot analysis of ENO1, TPI-1, and TAGLN2. Proteins from primary and metastatic tumors were separated by SDS-PAGE and transferred to PVDF membranes, followed by detection using the respective primary antibodies and an HRP-conjugated secondary antibody. In endometrial and ovarian cancers, the expression of ENO1 and TPI-1 was higher in metastatic tumors than in primary tumors, and the expression of TAGLN2 was lower in metastatic tumors than in primary tumors. Further, in cervical cancer, the expression of TPI-1 and TAGLN2 was lower in metastatic tumors than in primary tumors. <italic>P</italic> primary tumors, <italic>M</italic> metastatic tumors</p></caption><graphic xlink:href="13577_2012_53_Fig2_HTML" id="MO2"/></fig>
</p><p>In addition, immunohistochemical analysis was employed to assess ENO1. Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> shows representative examples of immunostaining for ENO1 in primary and metastatic tumors. Both western blotting and immunohistochemistry confirmed the findings of LC&#x02013;MS/MS analysis.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Representative immunostaining of ENO1 in primary and metastatic tumors. <bold>a</bold>, <bold>b</bold>, <bold>e</bold>, <bold>f</bold>, <bold>i</bold>, and <bold>j</bold> show primary tumors. <bold>c</bold>, <bold>d</bold>, <bold>g</bold>, <bold>h</bold>, <bold>k</bold>, and <bold>l</bold> show metastatic tumors. <bold>a</bold>, <bold>e</bold>, <bold>i</bold>, <bold>c</bold>, <bold>g</bold>, and <bold>k</bold> show HE staining. <bold>b</bold>, <bold>f</bold>, <bold>j</bold>, <bold>d</bold>, <bold>h</bold>, and <bold>l</bold> show ENO1 staining. ENO1 is overexpressed in metastatic tumors. All images are &#x000d7;400 magnification. <italic>Scale bars</italic> 100&#x000a0;mm. <italic>EC</italic> endometrial cancer (<bold>a</bold>&#x02013;<bold>d</bold>). <italic>CeC</italic> Uterine cervical cancer (<bold>e</bold>&#x02013;<bold>h</bold>). <italic>OC</italic> ovarian cancer (<bold>i</bold>&#x02013;<bold>l</bold>)</p></caption><graphic xlink:href="13577_2012_53_Fig3_HTML" id="MO3"/></fig>
</p></sec></sec><sec id="Sec13"><title>Discussion</title><p>The aim of this study was to identify biomarkers for brain metastases of gynecological malignancies, which have a different protein expression profile compared with primary tumors. Identification of proteins that are up-regulated or down-regulated in metastatic tumors may facilitate the detection and/or treatment of metastasis cancer. Therefore, we performed a comparative proteomic analysis of primary and metastatic gynecological cancers by LC&#x02013;MS/MS analysis of proteins extracted from FFPE samples. Western blotting and immunohistochemistry were also performed to confirm the results of LC&#x02013;MS/MS analysis. Until recently, protein extraction from formalin-fixed tissues was thought to be impossible because fixation by formalin creates strong intermolecular covalent bonds [<xref ref-type="bibr" rid="CR24">24</xref>]. However, successful protein extraction protocols have been established based on the heat-induced antigen retrieval technique widely applied for immunohistochemistry and proteomic analysis by LC&#x02013;MS/MS [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. In the present study, the protein expression profile of metastatic tumors was compared with that of primary tumors using extracts of FFPE samples. By LC&#x02013;MS/MS and scaffold analysis, 76 proteins were identified in 3 primary tumors and 101 proteins were found in 3 metastatic tumors. These proteins were related to a variety of biological processes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). To find candidate proteins, the 129 proteins that we identified were divided into 15 categories based on biological processes. Comparison of the distribution of these proteins between the primary and metastatic tumors showed differences in the expression of proteins related to metabolic, developmental, and multicellular organismal processes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Eight candidate proteins were selected that were predominantly or exclusively expressed by either the primary or metastatic tumors (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Several of the proteins identified in this study have been reported previously as possible metastasis-related proteins, including TAGLN2, TPI-1, ENO1, phosphatidylethanolamine binding protein (PEBP1), and mitochondrial ATP synthase alpha-subunit (ATP5A). TAGLN2 is a poorly characterized member of the calponin family. Its closest homologue is Transgelin 1/SM22a, an actin cross-linking protein [<xref ref-type="bibr" rid="CR27">27</xref>] that is thought to undergo down-regulation as an early marker of transformation [<xref ref-type="bibr" rid="CR28">28</xref>]. A recent study suggested that TAGLN2 has a negative influence on metastasis suppressing the invasive capacity of tumor cells [<xref ref-type="bibr" rid="CR23">23</xref>]. TPI-1 is an enzyme that catalyzes the reversible transformation of <sc>d</sc>-3-glyceraldehyde phosphate into dihydroxyacetone phosphate. Dihydroxyacetone phosphate is then transformed into <sc>d</sc>-3-glyceraldehyde phosphate to continue the glycolytic pathway, so TPI-1 has an important role in the process of glycolysis [<xref ref-type="bibr" rid="CR29">29</xref>]. Changes of enzyme activity have been reported under normal and pathological conditions, and overexpression of TPI-1 may activate both energy production and protein synthesis/degradation in rapidly growing tumor cells [<xref ref-type="bibr" rid="CR30">30</xref>]. Another study suggested that metabolic changes are associated with markedly enhanced survival and proliferation of breast cancer in the brain metastasis [<xref ref-type="bibr" rid="CR21">21</xref>]. ENO1 is a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate into phosphoenolpyruvate [<xref ref-type="bibr" rid="CR31">31</xref>]. ENO1 is the frequently deregulated in various types of cancer [<xref ref-type="bibr" rid="CR32">32</xref>]. In addition, ENO1 is more highly expressed in metastatic cancer cells compared with primary cancer cells, suggesting an oncogenic role of ENO1 [<xref ref-type="bibr" rid="CR22">22</xref>]. PEBP1 was originally identified as an endogenous inhibitor of Raf, and it negatively regulates the Raf/MEK/ERK-signaling cascade [<xref ref-type="bibr" rid="CR33">33</xref>]. It has been well established that PEBP1 suppresses the metastatic spread of tumor cells, and, moreover, the down-regulated expression of PEBP1 is observed in a number of human cancers [<xref ref-type="bibr" rid="CR34">34</xref>]. ATP5A was identified in tumor metastasized to liver and was overexpressed in metastatic tumor [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p>These reports indicated that there are several changes of protein expression between primary and metastatic tumor, and the metastasis may be supported by the expression changes. In the present study of clinical tumor samples, we identified the expression of TAGLN2 in primary tumors and we also identified TPI-1 and ENO1 in metastatic tumors, predominantly by LC&#x02013;MS/MS. Although the three proteins identified in this study have previously been suggested to be cancer-related, their functional role in gynecological cancer remains controversial. Also, we investigated the three proteins by western blotting. There were a few disparities in the results between western blot and LC&#x02013;MS/MS. We described that TPI-1 was predominantly identified in metastatic tumors. However, the TPI-1 expression in primary tumor was higher than metastatic tumor in cervical cancer. It has been reported that TPI-1 was represented overexpression in tumor cells [<xref ref-type="bibr" rid="CR30">30</xref>]. In addition, the overexpression of TPI-1 in metastatic tumor may not be a necessary character for metastasis. In any case, difference of cancer type may indicate difference of metastatic character. Further study is necessary to obtain their credibility as biomarkers.</p><p>Various molecular and genetic changes occur during the multistep process of tumor dissemination, and these have been called the &#x0201c;metastatic cascade&#x0201d; [<xref ref-type="bibr" rid="CR2">2</xref>]. This cascade starts with escape from the primary tumor by invasion of the surrounding tissue, entry into the bloodstream (intravasation), extravasation at a distant site, and finally survival and proliferation to form metastases [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. In this study, expression of TPI-1 and ENO1, which enhances cancer cell survival and proliferation, were higher in metastatic tumors than in primary tumors, and TAGLN2, which suppresses invasion of cancer cells, was lower in metastatic tumors than in primary tumors. The different expression of these proteins between primary and metastatic tumor may require characteristics for brain metastasis in these gynecological cancers. In addition, tubulin beta, 60S ribosomal protein L7 and Myosin light chain 6B were also identified in this study. Their role in tumor metastasis requires further investigation, but the role may be similar to that of proteins such as TPI-1, ENO1, and TAGLN2.</p><p>A recent study indicated that primary tumors can be regarded as genetically heterogeneous and contain subpopulations of cells with varying levels of metastatic potential [<xref ref-type="bibr" rid="CR38">38</xref>]. The data indicate that primary tumors are subpopulations of cells with different characteristics. This study indicated, by difference of identified proteins, that cancer cells can have different characteristics between primary tumors and metastatic tumors. The different characteristics might relate to brain metastasis in this study.</p><p>In conclusion, we identified several proteins that may be involved in brain metastasis of gynecological malignancies. Since our study consisted of a small number of patients, a larger study should be conducted in order to define the biological functions and influence in tumorigenesis and metastasis. In this study, we demonstrated the biomarker analysis tool using FFPE tissue-based proteomics by comparison of expression protein. Future studies using this tool will contribute to analysis of biomarkers, not only brain metastasis but also other organ metastasis such as lung and lymph node.</p></sec></body><back><ack><p>Hiroyumi Nishikawa is thanked for technical assistance.</p><sec id="d32e3483"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Marugame</surname><given-names>T</given-names></name><name><surname>Kamo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project</article-title><source>Jpn J Clin Oncol</source><year>2011</year><volume>41</volume><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyq169</pub-id><?supplied-pmid 20819836?><pub-id pub-id-type="pmid">20819836</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>IJ</given-names></name></person-group><article-title>Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture</article-title><source>Cancer Res</source><year>1990</year><volume>50</volume><fpage>6130</fpage><lpage>6138</lpage><?supplied-pmid 1698118?><pub-id pub-id-type="pmid">1698118</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirohashi</surname><given-names>S</given-names></name></person-group><article-title>Inactivation of the E-cadherin-mediated cell adhesion system in human cancers</article-title><source>Am J Pathol</source><year>1998</year><volume>153</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65575-7</pub-id><?supplied-pmid 9708792?><pub-id pub-id-type="pmid">9708792</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathoo</surname><given-names>N</given-names></name><name><surname>Chahlavi</surname><given-names>A</given-names></name><name><surname>Barnett</surname><given-names>GH</given-names></name><name><surname>Toms</surname><given-names>SA</given-names></name></person-group><article-title>Pathobiology of brain metastases</article-title><source>J Clin Pathol</source><year>2005</year><volume>58</volume><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1136/jcp.2003.013623</pub-id><?supplied-pmid 15735152?><pub-id pub-id-type="pmid">15735152</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paget</surname><given-names>S</given-names></name></person-group><article-title>The distribution of secondary growths in cancer of the breast. 1889</article-title><source>Cancer Metastasis Rev</source><year>1989</year><volume>8</volume><fpage>98</fpage><lpage>101</lpage><?supplied-pmid 2673568?><pub-id pub-id-type="pmid">2673568</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagundes</surname><given-names>H</given-names></name><name><surname>Perez</surname><given-names>CA</given-names></name><name><surname>Grigsby</surname><given-names>PW</given-names></name><name><surname>Lockett</surname><given-names>MA</given-names></name></person-group><article-title>Distant metastases after irradiation alone in carcinoma of the uterine cervix</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1992</year><volume>24</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/0360-3016(92)90671-4</pub-id><?supplied-pmid 1526855?><pub-id pub-id-type="pmid">1526855</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>A</given-names></name><name><surname>Webb</surname><given-names>MJ</given-names></name><name><surname>Keeney</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Hematogenous dissemination in corpus cancer</article-title><source>Gynecol Oncol</source><year>2001</year><volume>80</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1006/gyno.2000.6058</pub-id><?supplied-pmid 11161865?><pub-id pub-id-type="pmid">11161865</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anupol</surname><given-names>N</given-names></name><name><surname>Ghamande</surname><given-names>S</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases</article-title><source>Gynecol Oncol</source><year>2002</year><volume>85</volume><fpage>487</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1006/gyno.2002.6653</pub-id><?supplied-pmid 12051879?><pub-id pub-id-type="pmid">12051879</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (1969&#x02013;1996). Neurol Med Chir (Tokyo) 2003;43 Suppl:i,vii, 1&#x02013;111.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolomainen</surname><given-names>DF</given-names></name><name><surname>Larkin</surname><given-names>JM</given-names></name><name><surname>Badran</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>982</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.4.982</pub-id><?supplied-pmid 11844820?><pub-id pub-id-type="pmid">11844820</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Molecular portraits of human breast tumours</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1038/35021093</pub-id><?supplied-pmid 10963602?><pub-id pub-id-type="pmid">10963602</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cravatt</surname><given-names>BF</given-names></name><name><surname>Sorensen</surname><given-names>EJ</given-names></name></person-group><article-title>Chemical strategies for the global analysis of protein function</article-title><source>Curr Opin Chem Biol</source><year>2000</year><volume>4</volume><fpage>663</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/S1367-5931(00)00147-2</pub-id><?supplied-pmid 11102872?><pub-id pub-id-type="pmid">11102872</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesli</surname><given-names>C</given-names></name><name><surname>Borgia</surname><given-names>B</given-names></name><name><surname>Schliemann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>5406</fpage><lpage>5414</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0999</pub-id><?supplied-pmid 19491280?><pub-id pub-id-type="pmid">19491280</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>The hallmarks of cancer</article-title><source>Cell</source><year>2000</year><volume>100</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id><?supplied-pmid 10647931?><pub-id pub-id-type="pmid">10647931</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Systematic proteomic analysis of human hepotacellular carcinoma cells reveals molecular pathways and networks involved in metastasis</article-title><source>Mol BioSyst</source><year>2011</year><volume>7</volume><fpage>1908</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1039/c0mb00265h</pub-id><?supplied-pmid 21468425?><pub-id pub-id-type="pmid">21468425</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thongwatchara</surname><given-names>P</given-names></name><name><surname>Promwikorn</surname><given-names>W</given-names></name><name><surname>Srisomsap</surname><given-names>C</given-names></name><etal/></person-group><article-title>Differential protein expression in primary breast cancer and matched axillary node metastasis</article-title><source>Oncol Rep</source><year>2011</year><volume>26</volume><fpage>185</fpage><lpage>191</lpage><?supplied-pmid 21503584?><pub-id pub-id-type="pmid">21503584</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection</article-title><source>Lung Cancer</source><year>2009</year><volume>65</volume><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2008.10.024</pub-id><?supplied-pmid 19058872?><pub-id pub-id-type="pmid">19058872</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>SR</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Balgley</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry</article-title><source>J Histochem Cytochem</source><year>2006</year><volume>54</volume><fpage>739</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1369/jhc.5B6851.2006</pub-id><?supplied-pmid 16399996?><pub-id pub-id-type="pmid">16399996</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>JD</given-names></name><name><surname>Sajdera</surname><given-names>SW</given-names></name></person-group><article-title>Interference in the Lowry method for protein determination</article-title><source>Science</source><year>1970</year><volume>169</volume><fpage>97</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1126/science.169.3940.97-a</pub-id><?supplied-pmid 5447544?><pub-id pub-id-type="pmid">5447544</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>A</given-names></name><name><surname>Nesvizhskii</surname><given-names>AI</given-names></name><name><surname>Kolker</surname><given-names>E</given-names></name><name><surname>Aebersold</surname><given-names>R</given-names></name></person-group><article-title>Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search</article-title><source>Anal Chem</source><year>2002</year><volume>74</volume><fpage>5383</fpage><lpage>5392</lpage><pub-id pub-id-type="doi">10.1021/ac025747h</pub-id><?supplied-pmid 12403597?><pub-id pub-id-type="pmid">12403597</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>EI</given-names></name><name><surname>Hewel</surname><given-names>J</given-names></name><name><surname>Krueger</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Adaptation of energy metabolism in breast cancer brain metastases</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>1472</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3137</pub-id><?supplied-pmid 17308085?><pub-id pub-id-type="pmid">17308085</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry</article-title><source>Clin Exp Metastasis</source><year>2002</year><volume>19</volume><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1023/A:1015515119300</pub-id><?supplied-pmid 12090472?><pub-id pub-id-type="pmid">12090472</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duran</surname><given-names>MC</given-names></name><name><surname>Vega</surname><given-names>F</given-names></name><name><surname>Moreno-Bueno</surname><given-names>G</given-names></name><etal/></person-group><article-title>Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer</article-title><source>Proteomics Clin Appl</source><year>2008</year><volume>2</volume><fpage>1313</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1002/prca.200780020</pub-id><?supplied-pmid 21136925?><pub-id pub-id-type="pmid">21136925</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rait</surname><given-names>VK</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>TJ</given-names></name><name><surname>Mason</surname><given-names>JT</given-names></name></person-group><article-title>Modeling formalin fixation and antigen retrieval with bovine pancreatic RNase A II. Interrelationship of cross-linking, immunoreactivity, and heat treatment</article-title><source>Lab Invest</source><year>2004</year><volume>84</volume><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3700041</pub-id><?supplied-pmid 14767483?><pub-id pub-id-type="pmid">14767483</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Prieto DA, Hood BL, Darfler MM, et al. Liquid Tissue: proteomic profiling of formalin-fixed tissues. BioTechniques 2005;Suppl:32-5.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>A</given-names></name><name><surname>Kumai</surname><given-names>T</given-names></name><name><surname>Koizumi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Overexpression of heat shock protein 27 in squamous cell carcinoma of the uterine cervix: a proteomic analysis using archival formalin-fixed, paraffin-embedded tissues</article-title><source>Hum Pathol</source><year>2009</year><volume>40</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2008.06.010</pub-id><?supplied-pmid 18755499?><pub-id pub-id-type="pmid">18755499</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapland</surname><given-names>C</given-names></name><name><surname>Hsuan</surname><given-names>JJ</given-names></name><name><surname>Totty</surname><given-names>NF</given-names></name><name><surname>Lawson</surname><given-names>D</given-names></name></person-group><article-title>Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein</article-title><source>J Cell Biol</source><year>1993</year><volume>121</volume><fpage>1065</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1083/jcb.121.5.1065</pub-id><?supplied-pmid 8501116?><pub-id pub-id-type="pmid">8501116</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>JM</given-names></name><name><surname>Rogers-Graham</surname><given-names>K</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name></person-group><article-title>Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>9790</fpage><lpage>9799</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110086200</pub-id><?supplied-pmid 11773051?><pub-id pub-id-type="pmid">11773051</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>J</given-names></name><name><surname>van Rymenant</surname><given-names>M</given-names></name><name><surname>Lagae</surname><given-names>F</given-names></name></person-group><article-title>Enzymes in cancer. III. Triosephosphate isomerase activity of human blood serum in normal individuals and in individuals with various pathological conditions</article-title><source>Cancer</source><year>1961</year><volume>14</volume><fpage>1166</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(196111/12)14:6&#x0003c;1166::AID-CNCR2820140605&#x0003e;3.0.CO;2-J</pub-id><?supplied-pmid 14492728?><pub-id pub-id-type="pmid">14492728</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Tai</surname><given-names>LK</given-names></name><name><surname>Wong</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer</article-title><source>Mol Cell Proteomics</source><year>2005</year><volume>4</volume><fpage>1686</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1074/mcp.M400221-MCP200</pub-id><?supplied-pmid 16048908?><pub-id pub-id-type="pmid">16048908</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pancholi</surname><given-names>V</given-names></name></person-group><article-title>Multifunctional alpha-enolase: its role in diseases</article-title><source>Cell Mol Life Sci</source><year>2001</year><volume>58</volume><fpage>902</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1007/PL00000910</pub-id><?supplied-pmid 11497239?><pub-id pub-id-type="pmid">11497239</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamaguchi</surname><given-names>T</given-names></name><name><surname>Iizuka</surname><given-names>N</given-names></name><name><surname>Tsunedomi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma</article-title><source>Int J Oncol</source><year>2008</year><volume>33</volume><fpage>725</fpage><lpage>731</lpage><?supplied-pmid 18813785?><pub-id pub-id-type="pmid">18813785</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Yeung K, Seitz T, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999;401:173&#x02013;7.</mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Granovsky AE, Rosner MR. Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res. 2008;18:452&#x02013;7.</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Chang HJ, Lee MR, Hong SH, et al. Identification of mitochondrial FoF1-ATP synthase involved in liver metastasis of colorectal cancer. Cancer Sci. 2007;98:1184&#x02013;91.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christiano</surname><given-names>AP</given-names></name><name><surname>Yoshida</surname><given-names>BA</given-names></name><name><surname>Dubauskas</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Development of markers of prostate cancer metastasis. Review and perspective</article-title><source>Urol Oncol</source><year>2000</year><volume>5</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/S1078-1439(00)00070-3</pub-id><?supplied-pmid 10973711?><pub-id pub-id-type="pmid">10973711</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>NJ</given-names></name><name><surname>Steeg</surname><given-names>PS</given-names></name></person-group><article-title>Molecular basis of tumour metastasis</article-title><source>Cancer Surv</source><year>1993</year><volume>16</volume><fpage>175</fpage><lpage>199</lpage><?supplied-pmid 7688661?><pub-id pub-id-type="pmid">7688661</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navin</surname><given-names>N</given-names></name><name><surname>Kendall</surname><given-names>J</given-names></name><name><surname>Troge</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tumour evolution inferred by single-cell sequencing</article-title><source>Nature</source><year>2011</year><volume>472</volume><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1038/nature09807</pub-id><?supplied-pmid 21399628?><pub-id pub-id-type="pmid">21399628</pub-id></element-citation></ref></ref-list></back></article>